Managing Biologic Therapy and Small Molecule Use in IBD Patients during and after Cancer Diagnosis

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Current treatment options in gastroenterology

• Publication date

  2025-10-08

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s11938-025-00482-8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of Patients with IBD and History of Cancer

  2025cited by this paper
• ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease.

  2025cited by this paper
• Advanced Therapies for Inflammatory Bowel Disease and Risk of Skin Cancer: What’s New?

  2025cited by this paper
• Impact of cancer treatment in patients with inflammatory bowel disease: A systematic review and meta analysis.

  2024cited by this paper
• Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr: SAPPHIRE Registry.

  2024influential reference
• Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities

  2024cited by this paper
• AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients with Malignancy: Commentary.

  2024influential reference
• S1491 Use of Biologics and the Risk of Cancer in Inflammatory Bowel Disease: A Meta-Analysis

  2024cited by this paper
• Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis.

  2024cited by this paper
• Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease

  2023cited by this paper
• Upadacitinib in Crohn’s Disease: A Comprehensive Systematic Review of Efficacy and Safety

  2023cited by this paper
• RISK OF CANCER RECURRENCE IN PATIENTS WITH IMMUNE-MEDIATED DISEASES WITH USE OF IMMUNOSUPPRESSIVE THERAPIES: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS.

  2023cited by this paper
• Inflammatory Bowel Disease Treatment in Cancer Patients—A Comprehensive Review

  2023cited by this paper
• Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel diseases.

  2023cited by this paper
• Cancer in Inflammatory Bowel Disease.

  2022cited by this paper
• ECCO Guidelines on Inflammatory Bowel Disease and Malignancies.

  2022cited by this paper
• Risk of melanoma and nonmelanoma skin cancer with immunosuppressants Part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids.

  2022cited by this paper
• I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease.

  2022cited by this paper
• Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy.

  2022influential reference
• Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options

  2021cited by this paper
• Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

  2021cited by this paper
• Diagnosis and Management of Immune Checkpoint Inhibitor Colitis.

  2021cited by this paper
• Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study

  2021cited by this paper
• Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.

  2020cited by this paper
• Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases

  2020cited by this paper
• Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.

  2020cited by this paper
• AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor (ICI) Colitis and Hepatitis: Expert Review.

  2020cited by this paper
• Vedolizumab or TNF-antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: A retrospective cohort study.

  2020cited by this paper
• Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy

  2020cited by this paper
• The risk of extra-intestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies.

  2020cited by this paper
• Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden

  2020cited by this paper
• Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications.

  2020cited by this paper
• Checkpoint Inhibitor-Induced Colitis.

  2020cited by this paper
• Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers

  2019cited by this paper
• Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors—Results from the Swiss IBD Cohort Study

  2019cited by this paper
• Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment?

  2019cited by this paper
• Hormone Therapy for Cancer is a Risk Factor for Relapse of Inflammatory Bowel Diseases

  2019influential reference
• Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases

  2019cited by this paper
• Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

  2018cited by this paper
• Open: Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow‐up in the PYRAMID Registry

  2018cited by this paper
• Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis

  2018cited by this paper
• The TREAT Registry: Evolution of Knowledge From 1999 to 2017: Lessons Learned.

  2017influential reference
• Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014

  2017cited by this paper
• Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

  2017cited by this paper
• Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies

  2017influential reference
• High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease

  2017cited by this paper
• Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn’s Disease Treated With Infliximab [Remicade®] or Conventional Therapy

  2016cited by this paper
• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

  2016cited by this paper
• Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

  2016cited by this paper
• Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment.

  2016cited by this paper
• Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.

  2016cited by this paper
• Risk of cancer in inflammatory bowel disease: going up, going down, or still the same?

  2016cited by this paper
• Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.

  2016cited by this paper
• Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

  2015influential reference
• Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.

  2015cited by this paper
• Cancers complicating inflammatory bowel disease.

  2015cited by this paper
• Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation.

  2014cited by this paper
• Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease.

  2014cited by this paper
• Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.

  2014cited by this paper
• Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer

  2013influential reference
• Primary Sclerosing Cholangitis – Diagnosis, Prognosis and Management

  2013cited by this paper
• Declining Risk of Colorectal Cancer in Inflammatory Bowel Disease: An Updated Meta-analysis of Population-based Cohort Studies

  2013cited by this paper
• Use of azathioprine and the risk of cancer in inflammatory bowel disease.

  2013cited by this paper
• Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.

  2012cited by this paper
• Effects of cancer treatment on inflammatory bowel disease remission and reactivation.

  2012influential reference
• Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease

  2012cited by this paper
• Intestinal Cancer Risk in Crohn’s Disease: A Meta-Analysis

  2011cited by this paper
• A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

  2011cited by this paper
• Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

  2011cited by this paper
• Intestinal inflammation and cancer.

  2011cited by this paper
• Risk of Extra-Intestinal Cancer in Inflammatory Bowel Disease: Meta-Analysis of Population-Based Cohort Studies

  2010cited by this paper
• Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978–2003

  2009cited by this paper
• Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

  2008cited by this paper
• The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

  2007cited by this paper
• Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis.

  2006cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• The risk of colorectal cancer in ulcerative colitis: a meta-analysis

  2001cited by this paper
• Cancer risk in patients with inflammatory bowel disease.

  1999cited by this paper

• No citing papers are available for this paper.